Prognostic value of genetic alterations in colorectal cancer;Valeur pronostique des alterations genetiques des cancers colorectaux

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 5 BIS, 1996, Pages

  Laurent Puig, Pierre ^a,b  

^a INSTITUT CURIE   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Colonic neoplasm; DNA index; Genetic alterations; K ras; Mutation; p53; Prognosis

Indexed keywords

PROTEIN P53; RAS PROTEIN; DNA;

COLORECTAL CANCER; CONFERENCE PAPER; DNA CONTENT; GENE MUTATION; HETEROZYGOSITY; HUMAN; MARKER GENE; ONCOGENE K RAS; PROGNOSIS; TUMOR SUPPRESSOR GENE; CHEMISTRY; CLASSIFICATION; COLORECTAL TUMOR; GENETIC MARKER; GENETICS; PATHOPHYSIOLOGY; REVIEW;

COLORECTAL NEOPLASMS; DNA; GENETIC MARKERS; HUMANS; PROGNOSIS;

EID: 0029744607     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Dean PA, Vernava AM. Flow cytometric analysis of DNA content in colorectal carcinoma. Dis Colon Rectum 1992;35:95- 102.
2. Armitage NC, Robins RA, Evans DF, Turner DR, Baldwin RW, Hardcastle JD. The influence of tumor cell DNA abnormalities on survival in colorectal cancer. Br J Surg 1985;72:828-30.
3. Kokal WA, Sheibani K, Terz J, Harad JR. Tumor DNA content in the prognosis of colorectal carcinoma. JAMA 1986;255:3123-7.
4. Quirke P, Dixon MF, Clayden AD, Dudey P, Dyson JED, Williams NS, et al. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J Pathol 1987;151:285-91.
5. Scott NA, Wiegand HS, Moertel CG, Cha SS, Beart RW, Lieber MM. Colorectal cancer: Dukes stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987;122:1375-9.
6. Kokal WA, Gardine RI, Shebani K, Morris PL, Prager E, Zak IW, et al. Tumor DNA content in resectable primary colorectal carcinoma. Ann Surg 1989;209:188-93.
7. Jass JR, Mukawa K, Goh HS, Love SB, Capellaro D. Clinical importance of DNA content in rectal cancer measured by flow cytometry. J Clin Pathol 1989;42:254-9.
8. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman RM, Cha SS, Wieand HS, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-88.
9. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot B, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
10. Chapman MAS, Hardcastle JD, Armitage NCM. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 1995;76:383-7.
11. Rognum TO, Thorud E, Lund E. Survival of large bowel carcinoma patients with different DNA ploidy. Br J Cancer 1987;56:633-6.
12. Offerhaus GJA, De Feyter EP, Cornelisse CJ, Tersmette KWF, Floyd J, Kern SE, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9.
13. Finan PJ, Quirke P, Dixon MF, Dyson JED, Giles GR, Bird CC. Is DNA aneuploidy a good prognostic indicator in patients with advanced colorectal cancer? Br J Cancer 1986;54:327-30.
14. Scott NA, Rainwater LM, Wieand LH, Pemberton JH, Beart RW, Lieber MM. The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma. Dis Colon Rectum 1987;30:513-20.
15. Schutte B, Reydners MM, Wiggers T, Arends JW, Volovics L, Bosman FT, et al. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res 1987;47:5494-6.
16. Harlow SP, Eriken BL, Poggensee L, Chmiel JS, Scarpelli DG, Murad T, et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller stage C colonic adenocarcinoma. Cancer Res 1991;51:2403-9.
17. Jones DJ, Moore M, Schofield PF. Refining the prognostic signicance of DNA ploidy status in colorectal cancer: a prospective study. Int J Cancer 1988;41:206-10.
18. Sano T, Remvikos Y, Salmon RJ. Cytométrie en flux. Application à l'étude du contenu cellulaire en ADN des tumeurs colorectales. Gastroenterol Clin Biol 1988;12:629-36.
19. Giaretti W, Sciallero S, Geido BE, Aste H, Di Vinci A, D'Amore ESG. DNA flow cytometry of endoscopically examined colorectal carcinoma. Pathol Res Pract 1989;185:589-93.
20. Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leppert M, Nakamura Y, et al. Allelic loss in colorectal carcinoma. JAMA 1989;261:3099-103.
21. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sitonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
22. O'Conell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer. Cancer 1992;70:1732-9.
23. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-21.
24. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-51.
25. Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B, et al. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst 1992;84:1100-8.
26. Khine K, Smith DR, Goh HS. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer 1994;73:28-35.
27. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, el al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
28. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
29. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 1992;4:1-15.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
31. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994;70:293-6.
32. Bell SM, Scott N, Cross N, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
33. Bosari B, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994;86:681-7.
34. Mulder JWR, Bass IO, Polak MM, Goodman SN, Offerhaus GJA. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62.
35. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobson G, Nelson LS. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37:527-34.
36. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
37. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
38. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
39. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal carcinoma. Lancet 1992;340:1369-73.
40. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa M, et al. Expression of p53 protein in colorectal cancer and its relationship to short term prognosis. Cancer 1992;70:2778-84.
41. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993;68:399-402.
42. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node positive colorectal cancer patients. J Clin Oncol 1994;12:2043-50.
43. Dix BR, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70:585-90.
44. Bodner S, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
45. Lane D, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-3.
46. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1B-58kD tumor antigen and SV-40 large tumour antigen are physically associated with the same 54kD cellular protein in transformed cells. Cell 1982;28:387-94.
47. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
48. Prioleau J, Schnitt SJ. p53 antigen loss in stored paraffin slides. N Engl J Med 1995;332:1521-2.
49. Wynford-Thomas D. p53 in tumor pathology: can we trust immuno-histochemistry ? J Pathol 1992;166:329-33.
50. Hall PA, Lane D. p53 in tumor pathology: can we trust immunochemistry ? revisited. J Pathol 1994;172:1-4.
51. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
52. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
53. Wang L, Patel U, Ghosh L, Chen HC, Barnerjee S. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res 1993;53:717-20.
54. Cohn KH, Wang F, Desoto-Lapaix F, Solomon WB, Patterson LG, Arnold MR, et al. Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma. Lancet 1991;338:722-4.
55. Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI,WT1, Nm23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 1994;70:813-8.
56. Zeng ZS, Hsu S, Zhang ZF, Cohen AM, Enker WE, Turnbull AA, et al. High level of Nm23-H1 gene expression is associated with colorectal cancer progression not with metastases. Br J Cancer 1994;70:1025-30.
57. Heide I, Theide C, Poppe K, De Kant E, Huhn D, Rochlitz C. Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. Br J Cancer 1995;70:1267-71.
58. Royds JA, Cross SS, Silcocks PB, Scholefield JH, Rees RC, Stephenson TJ. Nm23 « antimetastatic » gene product expression in colorectal carcinoma. J Pathol 1994;172:261-6.
59. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
60. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
61. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Salmon RJ, Thomas G. Genetic instability of microsatellites in human colon cancer (abstract). Gastroenterology 1994;106:A390.
62. Meling GI, Lothe RA, Borresen AL, Graue C, Hauge S, Clausen OPF, et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. Br J Cancer 1993;67:93-8.
63. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-9.
64. Hayashi N, Arakawa H, Nagase H, Yanagisawa A, Kato Y, Ohta Y, et al. Genetic diagnosis identifies occult lymph node metastasis undetectable by the histopathological method. Cancer Res 1994;54:3853-6.
65. Lowe SW, Ruley HE, Jacks T, Houseman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
66. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, OwenShaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wild-type p53 gene. Cancer Res 1994;54:2287-91.
67. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of human MDR1 gene by ras and p53. Nature 1992;255:459-62.
68. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer different responsiveness to wild-type and mutant p53. Oncogene 1993;8:1529-35.
69. Seitz JF, Perrier H, Monges G, Giovannini M, Gouvemet J. Analyse multifactorielle des facteurs pronostiques et prédictifs de la réponse à la radiochimiothérapie concomitante dans les cancers épidermoïdes de l'œsophage. Intérêt de l'immunodétection de la protéine p53. Gastroenterol Clin Biol 1995;19:465-74.